AN ACT to create and enact a new subsection to section 43-15.3-08 of the North Dakota Century Code, relating to prohibited acts of drug manufacturers; and to provide a penalty.
House Bill No. 1473 aims to amend the North Dakota Century Code by creating a new subsection that outlines prohibited actions for drug manufacturers and their affiliates regarding the distribution of drugs purchased under the federal 340B drug discount program. The bill defines key terms such as 'contract pharmacy' and 'covered entity' and establishes penalties for manufacturers who interfere with the acquisition and dispensing of drugs by contract pharmacies on behalf of covered entities. This legislation seeks to ensure that eligible patients can access necessary medications without undue barriers imposed by manufacturers.
The bill's enactment will strengthen the rights of covered entities and contract pharmacies in North Dakota by prohibiting drug manufacturers from imposing restrictions that could hinder access to discounted medications. It introduces a class B misdemeanor penalty for violations, thereby enhancing compliance among manufacturers and potentially improving patient access to affordable medications. This change may also align state laws more closely with federal regulations governing drug pricing and distribution.
The general sentiment surrounding HB1473 appears to be supportive, as indicated by the voting results in both the House and Senate, where it passed with significant majorities (House: 71-17, Senate: 41-4). Stakeholders, including healthcare providers and patient advocacy groups, have expressed approval for measures that protect patient access to medications, although some concerns regarding the implications for manufacturers have been noted.
Notable points of contention include concerns from pharmaceutical manufacturers about the potential limitations on their ability to manage distribution and pricing strategies. Some legislators and industry representatives argue that the bill may inadvertently lead to increased costs for manufacturers, which could affect drug pricing overall. However, proponents argue that the bill is necessary to protect patient access and ensure compliance with federal drug pricing laws.